GlassScriptPhysician profile
Mamoon A Rasheed
NPI 1760448468
$8,192.89
in general payments reported to CMS, 2019-2025
51 companies · $936 in 2025
The $936 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,333 · 2020: $688 · 2021: $1,288 · 2022: $1,177 · 2023: $867 · 2024: $904 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,706.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,430.75 | 2021-2025 | |
| Novo Nordisk INC | $979.48 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $671.63 | 2019-2025 | |
| Lilly USA, LLC | $564.28 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $472.70 | 2019-2020 | |
| Glaxosmithkline, LLC. | $463.04 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $363.51 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $307.29 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $241.70 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $233.25 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $203.06 | 2021 | |
| Genzyme Corporation | $162.18 | 2021-2022 | |
| Astellas Pharma US INC | $145.34 | 2019-2020 | |
| Pulmonx Corporation | $142.86 | 2022 | |
| Boston Scientific Corporation | $120.64 | 2019 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mamoon Rasheed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.